FQHCs: Insulin & Epinephrine 340B Pricing Rule
- Health Resources and Services Governance (HRSA)-funded health centers must now provide insulin and injectable epinephrine to low-income patients at or below the 340B price.The new grant award terms,...
- HRSA is encouraging health centers to immediatly implement the updated award terms to ensure compliance and maximize patient benefit.
- During a Q&A session June 24, HRSA clarified that the requirement does not apply to Federally Qualified Health Center (FQHC) Look-Alikes or grantees not participating in the 340B...
HRSA-funded health centers must now provide insulin and epinephrine at or below 340B prices for low-income patients. These new stipulations, announced June 24, directly respond to a 2025 executive order designed to drive down drug costs. This mandate significantly impacts Federally Qualified Health centers (FQHCs) and requires immediate action. Grantees must implement these award terms to ensure compliance and maximize the benefit to patients. They should also consider updating patient costs according to the fluctuating 340B pricing. HRSA clarifies the requirement’s specifics. News Directory 3 provides key details on reporting procedures via Form 1C and the Budget Period Progress Report. Discover what’s next regarding internal policy adjustments and accurate progress reporting.
HRSA Health Centers to Provide Insulin, Epinephrine at Reduced Prices
Health Resources and Services Governance (HRSA)-funded health centers must now provide insulin and injectable epinephrine to low-income patients at or below the 340B price.The new grant award terms, announced June 24, are a response to the 2025 executive order aimed at lowering drug prices.
HRSA is encouraging health centers to immediatly implement the updated award terms to ensure compliance and maximize patient benefit. The executive order instructed the Department of Health and Human Services to ensure that grants are conditional upon health centers establishing practices to make these medications available at the reduced price.
During a Q&A session June 24, HRSA clarified that the requirement does not apply to Federally Qualified Health Center (FQHC) Look-Alikes or grantees not participating in the 340B Program. Grantees must report and demonstrate compliance via Form 1C, in conjunction with the annual budget Period Progress Report (BPR).
While HRSA has set the condition, individual grantees must develop internal practices to ensure low-income patients can access insulin and epinephrine at the 340B price. Given that 340B drug prices typically fluctuate quarterly, grantees should consider methods to update patient costs based on the most recent 340B price.
What’s next
HRSA grantees will need to establish internal policies and procedures to comply with the new requirements and accurately report their progress.